We've detected that Javascript is not enabled. It is required for an optimal survey taking experience.
Please check your browser's settings and make sure Javascript is turned on. Learn how to enable Javascript.

Skip survey header

New York State Opioid Use Disorder (OUD) in Pregnancy and Neonatal Abstinence Syndrome (NAS) Project Webinar: The Importance of Buprenorphine Waiver Training Evaluation Survey

New York State Opioid Use Disorder (OUD) in Pregnancy and Neonatal Abstinence Syndrome (NAS) Project September 2019 Webinar - The Importance of Buprenorphine Waiver Training

1. Please indicate your level of agreement with the following statements regarding the September 2019 New York State Opioid Use Disorder (OUD) in Pregnancy and Neonatal Abstinence Syndrome (NAS) Project Webinar - The Importance of Buprenorphine Waiver Training Evaluation Survey

*This question is required.

Space Cell	Strongly agree	Agree	Disagree	Strongly disagree	n/a
Dr. Paul Updike's presentation on Opioid Use Disorder in Pregnancy was informative.	Dr. Paul Updike's presentation on Opioid Use Disorder in Pregnancy was informative.: Strongly agree	Dr. Paul Updike's presentation on Opioid Use Disorder in Pregnancy was informative.: Agree	Dr. Paul Updike's presentation on Opioid Use Disorder in Pregnancy was informative.: Disagree	Dr. Paul Updike's presentation on Opioid Use Disorder in Pregnancy was informative.: Strongly disagree	Dr. Paul Updike's presentation on Opioid Use Disorder in Pregnancy was informative.: n/a
Dr. Paul Updike's presentation increased my knowledge of the pathophysiology and consequences of opioid use disorder.	Dr. Paul Updike's presentation increased my knowledge of the pathophysiology and consequences of opioid use disorder.: Strongly agree	Dr. Paul Updike's presentation increased my knowledge of the pathophysiology and consequences of opioid use disorder.: Agree	Dr. Paul Updike's presentation increased my knowledge of the pathophysiology and consequences of opioid use disorder.: Disagree	Dr. Paul Updike's presentation increased my knowledge of the pathophysiology and consequences of opioid use disorder.: Strongly disagree	Dr. Paul Updike's presentation increased my knowledge of the pathophysiology and consequences of opioid use disorder.: n/a
Dr. Paul Updike's presentation increased my knowledge of effective treament options for opioid use disorder in pregnancy.	Dr. Paul Updike's presentation increased my knowledge of effective treament options for opioid use disorder in pregnancy.: Strongly agree	Dr. Paul Updike's presentation increased my knowledge of effective treament options for opioid use disorder in pregnancy.: Agree	Dr. Paul Updike's presentation increased my knowledge of effective treament options for opioid use disorder in pregnancy.: Disagree	Dr. Paul Updike's presentation increased my knowledge of effective treament options for opioid use disorder in pregnancy.: Strongly disagree	Dr. Paul Updike's presentation increased my knowledge of effective treament options for opioid use disorder in pregnancy.: n/a
Dr. Paul Updike's presentation increased my knowledge of special concerns regarding opioid use disorder in pregnancy	Dr. Paul Updike's presentation increased my knowledge of special concerns regarding opioid use disorder in pregnancy: Strongly agree	Dr. Paul Updike's presentation increased my knowledge of special concerns regarding opioid use disorder in pregnancy: Agree	Dr. Paul Updike's presentation increased my knowledge of special concerns regarding opioid use disorder in pregnancy: Disagree	Dr. Paul Updike's presentation increased my knowledge of special concerns regarding opioid use disorder in pregnancy: Strongly disagree	Dr. Paul Updike's presentation increased my knowledge of special concerns regarding opioid use disorder in pregnancy: n/a

Other- please type in

3. If applicable to your professional position (i.e., MD, DO, NP, PA, etc.), are you more likely to register for Buprenorphine Waiver training than you were before the webinar?

If yes to the previous question, I would like to receive information about upcoming Buprenorphine Waiver Trainings in my area.

4. Do you have additional comments or feedback regarding the webinar?

5. Do you have ideas for future webinar topics?

6. If you would like NYS DOH to follow up with you directly, please provide your contact information.

First Name

Last Name

Title

Hospital Name

Email Address